Published in AIDS Weekly, January 15th, 2007
The data confirm the clinical antiviral activity of bevirimat shown in previous studies; however, the bevirimat plasma concentrations were lower than anticipated, suggesting that the tablet formulation used for this study did not deliver the drug as expected.
After 14 days of dosing with 400 mg of bevirimat tablets administered on top of patients' failing background regimens, an antiviral effect was seen in the bevirimat treatment group. Two out of twelve patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.